We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Will Life-Sciences Growth Drive Danaher (DHR) Q4 Earnings?
Read MoreHide Full Article
Danaher Corporation (DHR - Free Report) is scheduled to report fourth-quarter 2017 results before the opening bell on Jan 30. In the quarter to be reported, the company is expected to post strong growth in Life Sciences & Diagnostics business.
Last quarter, the company’s adjusted earnings beat the Zacks Consensus Estimate of 95 cents by 5.3%. The company has a consistent earnings surprise history, with an average positive surprise of 2.6% in the trailing four quarters.
Let’s see how things are shaping up for this announcement.
What’s Driving Better-Than-Expected Earnings?
Danaher has successfully positioned itself as a healthcare company, broadening its presence in the healthcare and dental markets. Potential prospects in the pharma and clinical end-markets bode well for the company in the upcoming quarters. Further, Danaher’s robust biopharma business should prove conducive to operating profit and bottom line in the fourth quarter.
The company has had an impressive 2017, delivering core growth acceleration, operating margin expansion as well as double-digit growth in earnings. Moreover, the company’s recent acquisitions continue to perform impressively, which have helped it improve productivity and drive growth. These factors should have a positive impact on the company’s upcoming results. The company also expects core growth rate to accelerate, in light of the improving order trends and recent acquisitions like Cepheid and Phenomenex.
Phenomenex has meaningfully enhanced its Life Sciences portfolio and is anticipated to help the company achieve a double-digit return on investment in less than five years. The Zacks Consensus Estimate for revenues from the Life Sciences & Diagnostics business in the to-be-reported quarter currently remains high at $1,453 million compared with the third-quarter reported revenues of $1,393 million. The Dental and Environmental & Applied Solutions segments also project decent sequential growth in sales, per our estimates.
Furthermore, the company’s constant focus on introduction of products to penetrate new markets has enabled it to gain competitive edge over peers. Danaher remains optimistic about core revenue and earnings growth, on the back of improving order trends and its operating culture, Danaher Business System (“DBS”). Historically, DBS has contributed to meaningful core revenue growth, adjusted earnings per share improvement and cash flow generation.
Earnings Whispers
Our proven model shows that Danaher has the right combination of the two key ingredients. A stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. This is perfectly the case here as you will see below:
Zacks ESP: Danaher has an Earnings ESP of +1.39%, as the Most Accurate estimate of $1.17 is pegged higher than the Zacks Consensus Estimate of $1.16. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: The company carries a Zacks Rank #3, which when combined with a positive ESP, makes us reasonably confident of an earnings beat.
We caution against stocks with a Zacks Rank #4 or 5 (Sell rated) going into the earnings announcement, especially when the company is seeing negative estimate revisions.
Other Stocks That Warrant a Look
Here are some other companies that you may want to consider, as our model shows that these have the right combination of elements to post an earnings beat this quarter:
Catalent, Inc. (CTLT - Free Report) , with an Earnings ESP of +1.91% and a Zacks Rank #3, is slated to report results on Feb 5.
Hess Corporation (HES - Free Report) , with an Earnings ESP of +1.97% and a Zacks Rank #3, is expected to report quarterly figures around Feb 5.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
Image: Bigstock
Will Life-Sciences Growth Drive Danaher (DHR) Q4 Earnings?
Danaher Corporation (DHR - Free Report) is scheduled to report fourth-quarter 2017 results before the opening bell on Jan 30. In the quarter to be reported, the company is expected to post strong growth in Life Sciences & Diagnostics business.
Last quarter, the company’s adjusted earnings beat the Zacks Consensus Estimate of 95 cents by 5.3%. The company has a consistent earnings surprise history, with an average positive surprise of 2.6% in the trailing four quarters.
Let’s see how things are shaping up for this announcement.
What’s Driving Better-Than-Expected Earnings?
Danaher has successfully positioned itself as a healthcare company, broadening its presence in the healthcare and dental markets. Potential prospects in the pharma and clinical end-markets bode well for the company in the upcoming quarters. Further, Danaher’s robust biopharma business should prove conducive to operating profit and bottom line in the fourth quarter.
The company has had an impressive 2017, delivering core growth acceleration, operating margin expansion as well as double-digit growth in earnings. Moreover, the company’s recent acquisitions continue to perform impressively, which have helped it improve productivity and drive growth. These factors should have a positive impact on the company’s upcoming results. The company also expects core growth rate to accelerate, in light of the improving order trends and recent acquisitions like Cepheid and Phenomenex.
Danaher Corporation Price and EPS Surprise
Danaher Corporation Price and EPS Surprise | Danaher Corporation Quote
Phenomenex has meaningfully enhanced its Life Sciences portfolio and is anticipated to help the company achieve a double-digit return on investment in less than five years. The Zacks Consensus Estimate for revenues from the Life Sciences & Diagnostics business in the to-be-reported quarter currently remains high at $1,453 million compared with the third-quarter reported revenues of $1,393 million. The Dental and Environmental & Applied Solutions segments also project decent sequential growth in sales, per our estimates.
Furthermore, the company’s constant focus on introduction of products to penetrate new markets has enabled it to gain competitive edge over peers. Danaher remains optimistic about core revenue and earnings growth, on the back of improving order trends and its operating culture, Danaher Business System (“DBS”). Historically, DBS has contributed to meaningful core revenue growth, adjusted earnings per share improvement and cash flow generation.
Earnings Whispers
Our proven model shows that Danaher has the right combination of the two key ingredients. A stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. This is perfectly the case here as you will see below:
Zacks ESP: Danaher has an Earnings ESP of +1.39%, as the Most Accurate estimate of $1.17 is pegged higher than the Zacks Consensus Estimate of $1.16. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: The company carries a Zacks Rank #3, which when combined with a positive ESP, makes us reasonably confident of an earnings beat.
We caution against stocks with a Zacks Rank #4 or 5 (Sell rated) going into the earnings announcement, especially when the company is seeing negative estimate revisions.
Other Stocks That Warrant a Look
Here are some other companies that you may want to consider, as our model shows that these have the right combination of elements to post an earnings beat this quarter:
Allison Transmission Holdings, Inc. (ALSN - Free Report) , with an Earnings ESP of +10.40% and a Zacks Rank #2, is expected to release quarterly numbers around Feb 5. You can see the complete list of today’s Zacks #1 Rank stocks here.
Catalent, Inc. (CTLT - Free Report) , with an Earnings ESP of +1.91% and a Zacks Rank #3, is slated to report results on Feb 5.
Hess Corporation (HES - Free Report) , with an Earnings ESP of +1.97% and a Zacks Rank #3, is expected to report quarterly figures around Feb 5.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
See Them Free>>